1. Discovery and Structure Activity Relationship of Glyoxamide Derivatives as anti-Hepatitis B Virus Agents. Amblard, F., S. Boucle, L. Bassit, Z. Chen, O. Sari, B. Cox, K. Verma, T. Ozturk, O. Ollinger-Russell, and R.F. Schinazi. Bioorganic & Medicinal Chemistry, 2021. 31: 115952. PMID[33421915]. [PMC7856252].
[PubMed]. HBV_02_2021.
2. Functional Comparison of Interferon-Α Subtypes Reveals Potent Hepatitis B Virus Suppression by a Concerted Action of Interferon-Α and Interferon-Γ Signaling. Chen, J., Y. Li, F. Lai, Y. Wang, K. Sutter, U. Dittmer, J. Ye, W. Zai, M. Liu, F. Shen, M. Wu, K. Hu, B. Li, M. Lu, X. Zhang, J. Zhang, J. Li, Q. Chen, and Z. Yuan. Hepatology, 2021. 73(2): p. 486-502. PMID[32333814].
[PubMed]. HBV_02_2021.
3. Immunostimulatory siRNA with a Uridine Bulge Leads to Potent Inhibition of HBV and Activation of Innate Immunity. Lan, T., Z. Wei, Y. He, S. Wan, L. Liu, B. Cheng, R. Li, H. Chen, G. Liu, and Z. Meng. Virology Journal, 2021. 18(1): 37. PMID[33602251]. [PMC7890953].
[PubMed]. HBV_02_2021.
4. Sulfamoylbenzamide-based Capsid Assembly Modulators for Selective Inhibition of Hepatitis B Viral Replication. Lee, Y.H., H.M. Cha, J.Y. Hwang, S.Y. Park, A.G. Vishakantegowda, A. Imran, J.Y. Lee, Y.S. Yi, S. Jun, G.H. Kim, H.J. Kang, S.J. Chung, M. Kim, H. Kim, and S.B. Han. ACS Med Chem Lett, 2021. 12(2): p. 242-248. PMID[33603970]. [PMC7883466].
[PubMed]. HBV_02_2021.
5. TMEM2 Binds to CSNK2A3 to Inhibit HBV Infection via Activation of the JAK/STAT Pathway. Zhou, H., X. Jia, K. Hu, Z. Mo, W. Xu, L. Peng, K. Wang, and X. Zhu. Exp Cell Res, 2021. 400(1): 112517. PMID[33582094].
[PubMed]. HBV_02_2021.
Patent Citations
6. Pyrazolo[4,3-C]pyridine Compounds for Use in the Treatment of HBV Infection. Kuduk, S.D. Patent. 2021. 2020-EP71672 2021023662: 42pp.
[Patent]. HBV_02_2021.
7. Bicyclic Compounds for the Treatment of Hepatitis B and Hepatitis D and Their Preparation. Vendeville, S. Patent. 2021. 2020-US45640 2021030278: 81pp.
[Patent]. HBV_02_2021.